Rare Disease · United Kingdom · In-Market

UK Spinal Muscular Atrophy Payer & HTA

All three funded SMA therapies in England reached the NHS through a conditional route. Zolgensma was recommended under HST15 and extended under HST24; nusinersen and risdiplam spent seven years in managed access before TA1162 moved them to routine commissioning.

HST15 and HST24TA1162 routine commissioningManaged access precedentUpdated Q3 2026
Reviewed by Sneha, Senior Analyst Last updated August 2026
Assess this report View Sample Assessment
Market United States United Kingdom GCC (Gulf) Stage
The Landscape

All three funded SMA therapies reached the NHS through a conditional route, and two of them took until TA1162 to convert that into routine commissioning.

NICE recommended onasemnogene abeparvovec under its Highly Specialised Technologies route in HST15, published 7 July 2021, for babies with 5q SMA carrying a biallelic SMN1 mutation and a clinical diagnosis of type 1 SMA, aged six months or under, or aged seven to twelve months with agreement from the national multidisciplinary team. In April 2023 NICE partially updated that guidance through HST24, extending the recommendation to presymptomatic babies aged twelve months and under. These are two appraisals covering two populations. The second widened eligibility rather than reversing a prior decision, and the presymptomatic recommendation depends on identifying affected babies before symptom onset, which is the operational constraint on that population rather than the funding decision itself.

The chronic therapies took the longer route. Nusinersen and risdiplam were both funded through time-limited managed access agreements from 2019, while NICE collected further evidence on their effectiveness, and only under TA1162 did NICE recommend them for routine NHS commissioning, superseding TA588 and TA755. Nusinersen is recommended under TA1162 for presymptomatic and symptomatic SMA in patients who have not responded successfully to gene therapy, which places it explicitly downstream of onasemnogene abeparvovec in the funded pathway. For a payer-facing team, the consequence is that the UK SMA pathway is now sequenced by NICE guidance itself, not only by clinical preference.

HST15 → HST24
onasemnogene abeparvovec recommended for symptomatic type 1 infants in July 2021, then extended to presymptomatic babies by partial update in April 2023
TA1162
supersedes TA588 and TA755, moving nusinersen and risdiplam from time-limited managed access to routine NHS commissioning
3 of 3
funded SMA therapies in England that reached the NHS through a conditional route before any routine commissioning decision
PAYER LANDSCAPE

UK SMA commissioning by agent, appraisal route, and where each one landed

Drug (Brand / INN)NICE AppraisalAccess RouteEligibilityCurrent Commissioning Status
Zolgensma (onasemnogene abeparvovec)HST15 (Jul 2021); HST24 (Apr 2023, partial update)Highly Specialised Technologies routeHST15: clinical diagnosis of type 1 SMA, 6 months or under, or 7 to 12 months with national MDT agreement. HST24: presymptomatic, 12 months and underNHS commissioned across both populations
Spinraza (nusinersen)TA588 (2019), superseded by TA1162Time-limited managed access from 2019Presymptomatic and symptomatic SMA in patients who have not responded successfully to gene therapyRoutine NHS commissioning under TA1162
Evrysdi (risdiplam)TA755, superseded by TA1162Time-limited managed access from 2019Per TA1162 criteria, alongside nusinersenRoutine NHS commissioning under TA1162

Sources: NICE highly specialised technologies guidance HST15, onasemnogene abeparvovec for treating spinal muscular atrophy, published 7 July 2021 and partially updated April 2023; NICE HST24, onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy, April 2023; NICE TA1162, nusinersen and risdiplam for treating spinal muscular atrophy, superseding TA588 and TA755.

Commercial Questions

What this assessment answers

Every section answers a named commercial question your team is asking, scoped to your asset.

01
What exactly did HST15 and HST24 recommend, and which infants does each one cover?

Delivers

  • The eligibility criteria under each appraisal, how the 2023 partial update widened the population, and where the boundary between the two now sits
02
What changed when TA1162 moved nusinersen and risdiplam from managed access to routine commissioning?

Delivers

  • The supersession of TA588 and TA755, the funded criteria under TA1162, and how the pathway is now sequenced relative to gene therapy
03
How should we position a new SMA asset against a pathway where NICE guidance already defines the sequence?

Delivers

  • Pathway-position analysis against the funded criteria, the conditional-route precedent every SMA therapy has followed, and the evidence commitments that route carries

Custom assessment delivered in 72 hours.

Assess this report
Contents

What's inside

Rare Disease · 24–32 pp · In-Market · Analyst report + Excel model + PowerPoint readout

1 UK SMA NHS Commissioning Overview — Three Therapies, Three Routes 4 pp
  • [object Object]
  • [object Object]
2 HST15 and HST24 — One Technology, Two Populations 6 pp
  • [object Object]
  • [object Object]
3 The Presymptomatic Population — Identification as the Binding Constraint 4 pp
  • [object Object]
  • [object Object]
4 TA1162 — Managed Access to Routine Commissioning 4 pp
  • [object Object]
  • [object Object]
5 Pathway Sequencing — Gene Therapy and Chronic Therapy Positions 5 pp
  • [object Object]
  • [object Object]
6 Sources and Methodology 3 pp
  • [object Object]
  • [object Object]
Appendix and source ledger included · 45-minute analyst readout included with delivery
Formats

Included with every brief

PDF
PDF Brief
Spinal Muscular Atrophy Payer & HTA Assessment — UK Complete Edition
25–30 page payer brief: the HST15 and HST24 appraisals, the presymptomatic identification constraint, and TA1162's move from managed access to routine NHS commissioning.
XLS
Excel Model
Payer Coverage Grid — Excel
NICE appraisal status, PAS/MAA terms, and estimated NHS cost for UK SMA agents in editable Excel format.
PPT
PowerPoint
Executive Readout — PowerPoint
12–15 slide readout deck for commercial team presentations, formatted to AXLRx design standards.
Methodology

How AXLRx builds this assessment

Prepared by MoatRx analysts.

This assessment is built from NICE Highly Specialised Technologies and Technology Appraisal guidance records, not secondary summaries. Every appraisal number, date, and eligibility criterion is verified against the live NICE record before inclusion.

Key sources: NICE HST15 (onasemnogene abeparvovec, published 7 July 2021, partially updated April 2023), NICE HST24 (presymptomatic SMA, April 2023), and NICE TA1162 (nusinersen and risdiplam), which supersedes TA588 and TA755.

  • HST15 and HST24 confirmed as two recommendations covering different populations, verified against the live NICE guidance record and not characterised as a rejection followed by a reversal
  • TA1162 confirmed as superseding both TA588 and TA755 and as moving nusinersen and risdiplam to routine NHS commissioning, verified against NICE guidance
  • No confidential commercial or patient access scheme net price is stated, and no annual NHS budget figure is asserted, because those values are not published
FAQ

Frequently asked questions

Deliverables
What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources
What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only: the NICE highly specialised technology evaluations for onasemnogene abeparvovec including its presymptomatic update, and the superseding NICE technology appraisal covering nusinersen and risdiplam. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered assessment.
Customisation
Can I tailor the assessment to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions, such as additional payer markets, pipeline agent profiles, or country-specific deep-dives, can be added to any standard assessment. Commission via the intake form to start.
Get Started

Commission this assessment

AXLRx Spinal Muscular Atrophy Payer & HTA is built for market access, HEOR, and pricing teams working a UK pathway where NICE guidance already defines the funded sequence. Custom assessment in 72 hours.

1
Submit your request

Specify indication, payer focus (NICE TA/LTVF, MAA, budget impact), and commercial question.

2
Scoping call

AXLRx analyst confirms payer scope, NICE pathway analysis, and delivery format.

3
Delivery

Research-verified assessment in 72 hours with optional analyst readout.

Assess this report View sample assessments